Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis

Surbhi Sidana, MD, Surendra Dasari, PhD, Taxiarchis Kourelis, MD, Angela Dispenzieri, MD, David L Murray, MD PhD, Rebecca L. King, MD, Ellen D. McPhail, MD, Marina Ramirez-Alvarado, Shaji K. Kumar, MD, Morie A. Gertz, MD

Blood (2019) 134 (Supplement_1): 1770.

https://doi.org/10.1182/blood-2019-121714

Published: 2019

Journal Articles

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Kentaro Narita, MD, Toshiki Terao, MD, Takafumi Tsushima, MD, Akihiro Kitadate, MD PhD, Daisuke Miura, MD, Masami Takeuchi, MD, Kosei Matsue, MD PhD

Blood (2019) 134 (Supplement_1): 1630.

https://doi.org/10.1182/blood-2019-126706

Published: 2019

Journal Articles

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Kaini Shen, MD, Yujun Dong, MD, Weijun Fu, Sr., MD PhD, Yu Wu, MD, Zhongxia Huang, Yongqiang Wei, PhD, Chunrui Li, MD PhD, Chunyan Sun, MD PhD, Wenrong Huang, Huihan Wang, MD PhD, Congli Zhang, Huilei Miao, Lu Zhang, MD, Xinxin Cao, MD, Daobin Zhou, MD, Jian Li, MD

Blood (2019) 134 (Supplement_1): 1870.

https://doi.org/10.1182/blood-2019-122087

Published: 2019

Journal Articles

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Blood (2019) 134 (Supplement_1): 3034.

https://doi.org/10.1182/blood-2019-128850

Published: 2019

Journal Articles

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Angela Dispenzieri, MD, Eftathios Kastritis, Ashutosh D Wechalekar, MB BS, MD FRCP, FRCPath, DM, Stefan O. Schönland, MD, Kihyun Kim, MD, Vaishali Sanchorawala, MD, Heather J Landau, MD, Fiona Kwok, FRACP,FRCPA,MBBS, Kenshi Suzuki, MD PhD, Raymond L Comenzo, MD, Deborah Berg, RN, MSN, Guohui Liu, PhD, Douglas V. Faller, MD PhD, Giampaolo Merlini, MD

Blood (2019) 134 (Supplement_1): 139.

https://doi.org/10.1182/blood-2019-124409

Published: 2019

Journal Articles

Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases

Sæmundur Rögnvaldsson, MD, Ingemar Turesson, MD PhD, Magnus Björkholm, MD PhD, Ola Landgren, MD PhD, Sigurður Yngvi Kristinsson, MD PhD

Blood (2019) 134 (Supplement_1): 5444.

https://doi.org/10.1182/blood-2019-131514

Published: 2019

Journal Articles

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Joon Young Hur, MD, Kang Kook Lee, MD, Sang Eun Yoon, MD, Sehhoon Park, MD, Jangho Cho, MD, Youjin Kim, MD, Eunseok Jeon, MD PhD, Jinoh Choi, MD PhD, Gayeon Lee, MD PhD, Byungjun Kim, MD PhD, Ju Hong Min, MD PhD, Jung Sun Kim, MD PhD, Jung Eun Lee, MD PhD, Joon Young Choi, MD PhD, Seok Jin Kim, MD PhD, Jun Ho Jang, MD PhD, Won-Seog Kim, MD PhD, Chul Won Jung, MD PhD, Kihyun Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3256.

https://doi.org/10.1182/blood-2018-99-114099

Published: 2018

Journal Articles

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Richa Manwani, MBBS, FRCPath, BSc, Faye Sharpley, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 3262.

https://doi.org/10.1182/blood-2018-99-116688

Published: 2018

Journal Articles

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

Anita D'Souza, MBBS, Kathryn E Flynn, PhD, Binod Dhakal, MBBS, Saurabh Chhabra, MD, Marcelo C Pasquini, MDMS, Parameswaran Hari, MBBS, MD

Blood (2018) 132 (Supplement 1): 1999.

https://doi.org/10.1182/blood-2018-99-114783

Published: 2018

Journal Articles

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Faye Sharpley, Richa Manwani, MBBS, FRCPath, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Helen Lachmann, Julian Gillmore, Carol Whelan, Philip Hawkins, Ashutosh D. Wechalekar

Blood (2018) 132 (Supplement 1): 4445.

https://doi.org/10.1182/blood-2018-99-114028

Published: 2018

Journal Articles

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Thomas Brannagan, Annabel K. Wang, Teresa Coelho, Marcia Waddington Cruz, Michael J. Polydefkis, Peter J. Dyck, Violaine Plante-Bordeneuve, John L. Berk, Fabio Barroso, Giampaolo Merlini, Isabel Conceição, Steven G. Hughes, Jesse G. Kwoh, Shiangtung W. Jung, Spencer Guthrie, Michael Pollock, Merrill D. Benson, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 498.

https://doi.org/10.1182/blood-2018-99-116995

Published: 2018

Journal Articles

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Jinny Park, MDPhD, Lalita Subedi, MS, Su Jung Park, MD, Oh kyung Lim, ChanJong Yoo, MD PhD, Jong-Suk Kim, MD PhD, Sun Yeou Kim, PhD

Blood (2018) 132 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2018-99-115711

Published: 2018

Journal Articles

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Blood (2017) 130 (Supplement 1): 3118.

https://doi.org/10.1182/blood.V130.Suppl_1.3118.3118

Published: 2017

Journal Articles

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

Tadeusz Robak, Isidro Jarque, Vasile Musteata, Peter Kiessling, Ute Massow, James Higginson, Rose Snipes, Stephen Jolles

Blood (2017) 130 (Supplement 1): 15.

https://doi.org/10.1182/blood.V130.Suppl_1.15.15

Published: 2017

Journal Articles

Analysis of Clinical Picture of Chronic Inflammatory Demyelinating Polyneuropathy in Adult T-Cell Leukemia-Lymphoma Patients after Allogeneic Stem Cell Transplantation

Mitsuhito Hirano, MD

Blood (2017) 130 (Supplement 1): 5182.

https://doi.org/10.1182/blood.V130.Suppl_1.5182.5182

Published: 2017

Journal Articles

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry

Taxiarchis V. Kourelis, Surendra Dasari, Jason D. Theis, Marina Ramirez-Alvarado, Paul J. Kurtin, Morie A. Gertz, Steven R. Zeldenrust, Roman M. Zenka, Ahmet Dogan, Angela Dispenzieri

Blood (2017) 129 (3): 299–306.

https://doi.org/10.1182/blood-2016-10-743997

Published: 2017

Includes: Supplemental data

Journal Articles

Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience

Ja Min Byun, Jeong-Ok Lee, Tae Min Kim, MD PhD, Bhumsuk Keam, Dae Seog Heo, Ki Hwan Kim, Soo-Mee Bang, Jong Seok Lee

Blood (2016) 128 (22): 4222.

https://doi.org/10.1182/blood.V128.22.4222.4222

Published: 2016

Journal Articles

Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement

Sandy W. Wong, MD, Denis Toskic, BS, Melissa Warner, BS, Alejandro Moreno-koehler, MPH, Daniel Fein, MD, Terry Fogaren, RN, BSN, Lisa Lee, MD, Colin Oliver, PhD MBA, Spencer D. Guthrie, MBA, Raymond L. Comenzo, MD

Blood (2016) 128 (22): 2136.

https://doi.org/10.1182/blood.V128.22.2136.2136

Published: 2016

Journal Articles

Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

Michaela Liedtke, MD, Raymond L. Comenzo, MD, Heather Landau, MD, Vaishali Sanchorawala, MD, Brendan M. Weiss, MD, Jeffrey A. Zonder, MD, Jackie Walling, MBChB, PhD, Gene G. Kinney, PhD, Martin Koller, MD MPH, Dale B. Schenk, PhD, Spencer D. Guthrie, MBA, Enchi Liu, PhD, Morie A. Gertz, MD MACP

Blood (2016) 128 (22): 647.

https://doi.org/10.1182/blood.V128.22.647.647

Published: 2016

Journal Articles

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Efstathios Kastritis, MD, Giampaolo Merlini, MD, Ioannis Papassotiriou, PhD, Paolo Milani, MD, Evangelos Terpos, Marco Basset, MD, Athanasios Akalestos, Francesca Russo, Erasmia Psimenou, Filia Apostoloakou, Maria Roussou, Maria Gavriatopoulou, Despina Fotiou, Dimitrios Ziogas, Constantinos Pamboucas, Elektra Papadopoulou, Meletios A Dimopoulos, Giovanni Palladini, MD PhD

Blood (2016) 128 (22): 648.

https://doi.org/10.1182/blood.V128.22.648.648

Published: 2016

NARROW

Immunoglobulin Variable Gene Region (IGVL) Usage Correlates with Distinct Clinical Presentation in IgM Versus Non-IgM Light Chain Amyloidosis

Clinical Features, Diagnosis, and Prognosis of 22 Cases of Neurolymphomatosis : A Single-Institution Experience over 12 Years

Doxycycline Combined with Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Patients with Mayo 2004 Stage II-III Light-Chain Amyloidosis: A Randomized Controlled Multicenter Study

Preliminary Phase 1 Data on the Safety and Efficacy of a Novel PET Radiotracer, 124 I-p5+14, for Imaging Systemic Amyloidosis

Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients (Pts) with Relapsed/Refractory Primary Systemic AL Amyloidosis (RRAL)

Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases

Bortezomib-Based First Line Treatment for AL Amyloidosis Patients Who Are Not Candidate for Stem Cell Transplantaion

Achieving a Difference in Involved and Uninvolved Light Chains (dFLC) of Less Than 10mg/L Is the New Goal of Therapy in Systemic AL Amyloidosis: Analysis of 916 Patients Treated Upfront with Bortezomib-Based Therapy

Adjuvant Doxycycline to Enhance Anti-Amyloid Effects: Results from the DUAL (Doxycycline to Upgrade response in AL amyloidosis) Study

A Novel Mass Spectrometry Method to Identify the Serum Monoclonal Light Chain Component and Infer Organ Involvement in Systemic Light Chain Amyloidosis

Long-Term Update from the Open-Label Extension of the NEURO-TTR Study in Patients with Hereditary Transthyretin Amyloidosis

Glutathione Ameliorates Bortezomib (Velcade) -Induced Neuronal Toxicity in N2a and SHSY5Y Cells

Efficacy of Lenalidomide As Salvage Therapy for Patients with AL Amyloidosis

Phase II, Multiple-Dose Study of Anti-FcRn Antibody, Rozanolixizumab (UCB7665), in Patients with Primary Immune Thrombocytopenia: Interim Analysis

Analysis of Clinical Picture of Chronic Inflammatory Demyelinating Polyneuropathy in Adult T-Cell Leukemia-Lymphoma Patients after Allogeneic Stem Cell Transplantation

Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry

Diagnosis of Secondary Peripheral Neurolymphomatosis: A Multi-Center Experience

Impact of Cardiac Stage and Hematologic Response on AL Amyloidosis Patients with Renal Involvement

Organ Biomarker Responses in Patients with Light Chain Amyloidosis Treated with NEOD001 Are Independent of Previous Hematologic Response

Growth Differentiation Factor-15 (GDF-15) Is a New Biomarker with Independent Prognostic Significance for Survival and Renal Outcomes in Different Cohorts of Patients with Light Chain (AL) Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only